Escient Pharmaceuticals Initiates Phase 2 Pacific Study Evaluating EP547, an Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus Portfolio News / By Karina Tin November 17, 2022
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock Portfolio News / By Karina Tin November 17, 2022
Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires Portfolio News / By Karina Tin November 16, 2022
Casma Therapeutics Raises $46.0 M in Series C Funding Portfolio News / By Karina Tin November 15, 2022
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update Portfolio News / By Karina Tin November 14, 2022
Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in Portfolio News / By Karina Tin November 10, 2022
RAPT Therapeutics Reports Third Quarter 2022 Financial Results Portfolio News / By Karina Tin November 10, 2022
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Portfolio News / By Karina Tin November 10, 2022
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies Portfolio News / By Karina Tin November 10, 2022
eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Portfolio News / By Karina Tin November 7, 2022